Shield Therapeutics Looking At US Options For Feraccru

 
• By John Davis

The UK biotech has revised its business strategy over the past year, and Shield's CEO believes the company's lead product for iron deficiency is now well positioned to compete with current and potential entrants in the therapeutic sector.  

Iron
Iron deficiency can be an issue in a number of conditions. • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas